动态血糖监测(CGM)联合胰岛素强化治疗应用于2型糖尿病肾病的临床研究

A Clinical Study of Ambulatory Glucose Monitoring(CGM)Combined with Intensive Insulin Therapy in Type 2 Diabetic Nephropathy

目的分析动态血糖监测(CGM)联合胰岛素强化治疗应用于2型糖尿病肾病的临床疗效。方法将2022年6月-2023月12月乐平市人民医院收治的2型糖尿病肾病患者108例纳入本次研究,随机分为两组,各54例。两组均接受谷赖胰岛素联合甘精胰岛素强化治疗,对照组使用传统七段血糖监测,观察组使用动态血糖监测。比较两组的血糖指标水平、胰岛功能指标水平、肾功能情况和低血糖发生率。结果治疗后,两组FPG、2hPG、HbA1c、HOMA-IR、Cr、UACR均降低,HOMA-β、eGFR升高,观察组均优于对照组(P<0.05);治疗后,观察组低血糖发生率低于对照组(P<0.05)。结论动态血糖监测(CGM)联合胰岛素强化治疗应用于2型糖尿病肾病能够减少终末期肾病和肾脏透析概率,低糖尿病肾病患者死亡率,为2型糖尿病肾病的临床治疗提供参考。

Objective To analyze the clinical efficacy of dynamic glucose monitoring(CGM)combined with insulin intensive therapy applied to type 2 diabetic nephropathy.Methods 108 patients with type 2 diabetic nephropathy admitted to Leping People's Hospital from June 2022 to December 2023 were included in this study and randomly divided into two groups of 54 cases each.Both groups received intensive treatment with glutaraldehyde insulin combined with glucagon insulin,the control group used traditional seven-segment glucose monitoring,and the observation group used dynamic glucose monitoring.Compare the levels of blood glucose indexes,levels of pancreatic function indexes,renal function conditions and incidence of hypoglycemia in the two groups.Results After treatment,FPG,2hPG,HbA1c,HOMA-IR,Cr,UACR were reduced in both groups,and HOMA-βand eGFR were increased,and the observation group was better than the control group(P<0.05);after treatment,the incidence of hypoglycemia in the observation group was lower than that in the control group(P<0.05).Conclusion Dynamic glucose monitoring(CGM)combined with insulin intensive therapy applied to type 2 diabetic nephropathy can reduce the probability of end-stage renal disease and renal dialysis,low mortality rate of patients with diabetic nephropathy,and provide reference for the clinical treatment of type 2 diabetic nephropathy.